KRAS: the Achilles’ heel of pancreas cancer biology
Journal of Clinical Investigation · 15.08.2025 · 135 (16)
DOI: 10.1172/jci191939 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.08.2025. Verfasst von Kristina Drizyte-Miller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Mutation. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The genetic landscape of pancreatic ductal adenocarcinoma (PDAC) is well-established and dominated by four key genetic driver mutations. Mutational activation of the KRAS oncogene is the initiating genetic event, followed by genetic loss of function of the CDKN2A , TP53 , and SMAD4 tumor suppressor genes. Disappointingly, this information has not been leveraged to develop clinically effective targeted therapies for PDAC treatment, where current standards of care remain cocktails of conventional cytotoxic drugs. Nearly all (~95%) PDAC harbors KRAS mutations, and experimental studies have validated the essential role of KRAS mutation in PDAC tumorigenic and metastatic growth. Identified in 1982 as the first gene shown to be aberrantly activated in human cancer, KRAS has been the focus of intensive drug discovery efforts. Widely considered “undruggable,” KRAS has been the elephant in the room for PDAC treatment. This perception was shattered recently with the approval of two KRAS inhibitors for the treatment of KRAS G12C -mutant lung and colorectal cancer, fueling hope that KRAS inhibitors will lead to a breakthrough in PDAC therapy. In this Review, we summarize the key role of aberrant KRAS signaling in the biology of pancreatic cancer; provide an overview of past, current, and emerging anti-KRAS treatment strategies; and discuss current challenges that limit the clinical efficacy of directly targeting KRAS for pancreatic cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center.
- Department of Medicine.
- Department of Pharmacology, and.
- Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Drizyte-Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025). KRAS: the Achilles’ heel of pancreas cancer biology. Journal of Clinical Investigation, 135(16). https://doi.org/10.1172/jci191939
Vancouver
Drizyte-Miller K, Talabi T, Somasundaram A, Cox AD, Der CJ. KRAS: the Achilles’ heel of pancreas cancer biology. Journal of Clinical Investigation. 2025;135(16). doi:10.1172/jci191939
BibTeX
@article{DrizyteMiller2025,
author = {Drizyte-Miller, Kristina and Talabi, Taiwo and Somasundaram, Ashwin and Cox, Adrienne D and Der, Channing J},
title = {KRAS: the Achilles’ heel of pancreas cancer biology},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {16},
doi = {10.1172/jci191939}
}
EUVIMED